Search
for
Sort by
Research 61–90 of 305
- Expanding the Availability of Scalp Cooling to All Patients at Risk of Chemotherapy-Induced Alopecia
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
- Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
- Scalp hypothermia as a preventative measure for chemotherapy‐induced alopecia: a review of controlled clinical trials
- Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
- Preclinical Development and Phase I Study of ZSYY001, a Polymeric Micellar Paclitaxel for Advanced Solid Tumor
- Cancer-Related Alopecia: From Etiologies to Global Management
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
- Mild oxidative stress protects against chemotherapy-induced hair loss
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Beyond the Follicle: A Narrative Review on How Systemic Diseases and Drugs Affect Alopecia
- Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence
- Advancements in non-laser energy-based devices in trichology: A comprehensive review
- Microneedles as transdermal drug delivery system for enhancing skin disease treatment
- Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
- Photobiomodulation for the management of alopecia: mechanisms of action, patient selection and perspectives
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
- Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients
- Annurca Apple Polyphenols Protect Murine Hair Follicles from Taxane Induced Dystrophy and Hijacks Polyunsaturated Fatty Acid Metabolism toward β-Oxidation
- Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity
- Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy
- Low-Intensity Ultrasound as a Potential Intervention Strategy to Protect Human Scalp Hair Follicles from Taxane-Induced Toxicity
- Taxane-induced alopecia: A historical review of patients with ovarian or breast cancer treated with with paclitaxel, docetaxel or paclitaxel poliglumex
- Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer
- Permanent Alopecia in Breast Cancer Patients: Role of Taxanes and Endocrine Therapies
- 1400 Low-intensity ultrasound protects human scalp hair follicles from taxane-induced toxicity
- 506 Taxane chemotherapy promotes aging of human hair follicles and their stem cells